Evidence map›Paper›PMID 40363882›Full record

ReviewMolecules (Basel, Switzerland)2025

Thiosemicarbazone-Based Compounds: Cancer Cell Inhibitors with Antioxidant Properties.

Olga Garbuz, Emil Ceban, Dorin Istrati, Nadejda Railean, Ion Toderas, Aurelian Gulea

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Tris[Antioxidants (Basel, Switzerland) · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Olga GarbuzLaboratory of Systematics and Molecular Phylogenetics, Institute of Zoology, Moldova State University, 1 Academiei Street, MD-2028 Chisinau, Moldova.ORCID 0000-0001-8783-892X
Emil CebanDepartment of Urology and Surgical Nephrology, University of Medicine and Pharmacy "Nicolae Testemitanu", 165 Stefan cel Mare si Sfant Bd., MD-2004 Chisinau, Moldova.ORCID 0000-0002-1583-2884
Dorin IstratiDepartment of Urology and Surgical Nephrology, University of Medicine and Pharmacy "Nicolae Testemitanu", 165 Stefan cel Mare si Sfant Bd., MD-2004 Chisinau, Moldova.ORCID 0000-0002-8795-5277
Nadejda RaileanLaboratory of Systematics and Molecular Phylogenetics, Institute of Zoology, Moldova State University, 1 Academiei Street, MD-2028 Chisinau, Moldova.ORCID 0000-0001-7818-9200
Ion ToderasLaboratory of Systematics and Molecular Phylogenetics, Institute of Zoology, Moldova State University, 1 Academiei Street, MD-2028 Chisinau, Moldova.ORCID 0000-0003-1599-838X
Aurelian GuleaLaboratory of Advanced Materials in Biopharmaceutics and Technics, Institute of Chemistry, Moldova State University, 60 Mateevici Street, MD-2009 Chisinau, Moldova.ORCID 0000-0003-2010-7959

Funding

Research and Innovation Project 24.80012.8007.01SEsubprogram 010602subprogram 010701
6 · The paper itself

Abstract

Thiosemicarbazone-based compounds have attracted significant attention in recent years due to their potential as inhibitors of cancer cell proliferation. They not only exhibit strong antiproliferative effects but also possess antioxidant properties that are crucial in combating oxidative stress linked to cancer progression. This review highlights specific compounds that not only exhibit significantly higher antiproliferative activities but also demonstrate lower toxicity compared to traditional chemotherapy agents. This is important because it suggests that these compounds could provide better treatment options while reducing the side effects often associated with chemotherapy. A detailed analysis of the structure-activity relationships (SARs) reveals that the unique structural features of these compounds play a crucial role in their enhanced effectiveness. Understanding which molecular characteristics contribute to improved activity will be key for future compound design. The findings from this study emphasize the need for further exploration and development of these novel agents. By investigating their biological mechanisms and optimizing their structures, researchers can improve cancer treatment strategies, providing safer and more effective options for patients. Despite substantial previous research on thiosemicarbazones and isothiosemicarbazones, the field still holds many unknowns and opportunities for discovery. Studying coordination chemistry with 3

Indexed as

Antineoplastic AgentsAntioxidantsNeoplasmsThiosemicarbazonesAnimalsCell ProliferationHumansMolecular StructureOxidative StressStructure-Activity RelationshipAntineoplastic AgentsAntioxidantsThiosemicarbazonesanticancer activityantioxidant activitiescoordination compoundsselectivitysynthetic compoundthiosemicarbazone

Identifiers

PMID40363882
PMCPMC12073680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.